{"id":473401,"date":"2021-04-08T04:33:24","date_gmt":"2021-04-08T08:33:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473401"},"modified":"2021-04-08T04:33:24","modified_gmt":"2021-04-08T08:33:24","slug":"ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/","title":{"rendered":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc."},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MILWAUKEE<\/span>, April 8, 2021<\/span> \/PRNewswire\/ — Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).\u00a0 The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects.<\/p>\n

Click here to learn more about the investigation https:\/\/www.ademilaw.com\/case\/fibrogen-inc<\/a> or call Guri Ademi<\/span> toll-free at 866-264-3995. There is no cost or obligation to you. <\/p>\n

The investigation focuses on whether Fibrogen properly disclosed the data underlying the safety of Fibrogen’s proposed anemia drug, roxadustat, in its Phase 3 application with the FDA.\u00a0 On April 6<\/span>, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is.\u00a0 Fribrogen acknowledged that it had changed parameters used to analyze heart safety data for roxadustat in patients with anemia from chronic kidney disease. The false criteria yielded more flattering data, which\u00a0FibroGen first made public in 2019. Fibrogen said it was conducting an “internal review to ensure such issues do not occur in the future.”<\/p>\n

If you wish to obtain additional information or have information about this investigation, please contact Guri Ademi<\/span> either at gademi@ademilaw.com<\/a> or toll-free: 866-264-3995, https:\/\/www.ademilaw.com\/case\/fibrogen-inc<\/a>.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

We specialize in securities fraud and shareholder litigation.\u00a0 For more information, please feel free to call us. \u00a0Attorney advertising. Prior results do not guarantee similar outcomes. <\/p>\n

Contact:
Ademi LLP
Guri Ademi<\/span>
3620 East Layton Ave.
Cudahy, WI<\/span> 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com<\/a><\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc-301264722.html<\/a><\/p>\n

SOURCE Ademi LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MILWAUKEE, April 8, 2021 \/PRNewswire\/ — Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).\u00a0 The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects. Click here to learn more about the investigation https:\/\/www.ademilaw.com\/case\/fibrogen-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Fibrogen properly disclosed the data underlying the safety of Fibrogen’s proposed anemia drug, roxadustat, in its Phase 3 application with the FDA.\u00a0 On April 6, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is.\u00a0 Fribrogen acknowledged that it had changed parameters used to analyze heart safety data … <\/p>\n

Continue reading “Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473401","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdemi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MILWAUKEE, April 8, 2021 \/PRNewswire\/ — Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).\u00a0 The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects. Click here to learn more about the investigation https:\/\/www.ademilaw.com\/case\/fibrogen-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Fibrogen properly disclosed the data underlying the safety of Fibrogen’s proposed anemia drug, roxadustat, in its Phase 3 application with the FDA.\u00a0 On April 6, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is.\u00a0 Fribrogen acknowledged that it had changed parameters used to analyze heart safety data … Continue reading "Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T08:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.\",\"datePublished\":\"2021-04-08T08:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG36167&sd=2021-04-08\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/\",\"name\":\"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG36167&sd=2021-04-08\",\"datePublished\":\"2021-04-08T08:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG36167&sd=2021-04-08\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG36167&sd=2021-04-08\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/","og_locale":"en_US","og_type":"article","og_title":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk","og_description":"PR Newswire MILWAUKEE, April 8, 2021 \/PRNewswire\/ — Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN).\u00a0 The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects. Click here to learn more about the investigation https:\/\/www.ademilaw.com\/case\/fibrogen-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on whether Fibrogen properly disclosed the data underlying the safety of Fibrogen’s proposed anemia drug, roxadustat, in its Phase 3 application with the FDA.\u00a0 On April 6, FibroGen admitted to presenting roxadustat data manipulated to make the anemia drug look safer than it is.\u00a0 Fribrogen acknowledged that it had changed parameters used to analyze heart safety data … Continue reading \"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T08:33:24+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.","datePublished":"2021-04-08T08:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/","name":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08","datePublished":"2021-04-08T08:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG36167&sd=2021-04-08"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ademi-llp-investigates-claims-of-securities-fraud-against-fibrogen-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473401"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473401\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}